Axel Grothey
MD
Director of GI Cancer Research
👥Biography 个人简介
Axel Grothey is a pioneer in the treatment of refractory colorectal cancer, having led the CORRECT trial that established regorafenib and the RECOURSE trial that established TAS-102/trifluridine-tipiracil as approved salvage therapies. His clinical trial leadership has significantly expanded the therapeutic landscape for patients who progress on standard regimens. He has been instrumental in developing treatment algorithms and sequencing strategies for advanced CRC. His work on maintenance therapy and chemotherapy holidays has also shaped CRC management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Axel Grothey 的研究动态
Follow Axel Grothey's research updates
留下邮箱，当我们发布与 Axel Grothey（West Cancer Center and Research Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment